{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-23-000037","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2023-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.267545+00:00","generated_at":"2026-06-17T23:51:58.886078+00:00","sec_items":["4.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Xeris Biopharma replaces KPMG with Ernst & Young as independent auditor","bullets":["Audit committee dismissed KPMG as independent registered public accounting firm on March 13, 2023.","KPMG's reports for FY2022 and FY2021 had no adverse opinion except for a lease accounting change.","No disagreements or reportable events occurred during the audit periods or interim period through March 13, 2023.","Ernst & Young engaged as new independent auditor for the fiscal year ending December 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-23-000037","json":"https://secwatch.observer/filing/0001867096-23-000037.json","markdown":"https://secwatch.observer/filing/0001867096-23-000037.md","text":"https://secwatch.observer/filing/0001867096-23-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000037/0001867096-23-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000037/xers-20230313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T23:51:58.886078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7b40b8a67a7c47a99b9c3bf3791272d4027c328c","claim":"Xeris Biopharma Holdings, Inc. engaged Ernst & Young LLP as its auditor.","evidence_excerpt":"On March 13, 2023, the Audit Committee of the Board approved the engagement of Ernst & Young LLP (\"E&Y\") as its new independent registered public accounting firm to audit the Company's financial statements for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000037/0001867096-23-000037-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Ernst & Young LLP"}],"fact_type":"auditor_change"},{"claim_id":"af58ee5abce0956d5fbbb158643d52145db71bae","claim":"Xeris Biopharma Holdings, Inc. dismissed KPMG LLP as its auditor.","evidence_excerpt":"On March 13, 2023, the audit committee (the \"Audit Committee\") of the board of directors (the \"Board\") of Xeris Biopharma Holdings, Inc. and subsidiaries (the \"Company\") approved the dismissal of KPMG LLP (\"KPMG\") as the Company's independent registered public accounting firm and KPMG was dismissed.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000037/0001867096-23-000037-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"KPMG LLP"},{"label":"Successor","value":"Ernst & Young LLP"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}